Heart Rhythm 2026:

Heart Rhythm 2026:
GLP-1 Therapy Associated with Lower Risk of Developing AF and Improved Overall Survival Beyond Weight Loss

Source: University of Virginia (UVA Health), May 26, 2026, based on data presented at Heart Rhythm 2026.

* GLP-1 drugs were associated with:
* Lower risk of new-onset atrial fibrillation (AF)
* Better survival
* Benefits appeared independent of weight loss, suggesting anti-inflammatory effects.
* Semaglutide showed the strongest association with AF reduction.
* Researchers believe reducing cardiac inflammation and epicardial fat may help prevent AF.